efeitos da inibição do sistema renina-angiotensina-aldosterona e do ...

a trend towards an increase in LVEF (absolute difference between groups 2.3%, p=0.094). The
addition of carvedilol was safe, haemodynamically well-tolerated, and not associated with
symptomatic bradycardia.
Conclusion: in patients with CCC optimisation of treatment with enalapril and spironolactone
followed by the addition of carvedilol, was safe and associated with benefits in cardiac function
and clinical status. Larger trials are needed to show effects on mortality and/or hospitalisation.
156